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and secretory antibody defenses, mucosal-
associated lymphoid tissue (MALT) —
 populated by distinct dendritic, T, B, 
and accessory cell populations — acts as 
an inductive tissue for priming of anti-
gen-presenting cells at remote eff ector 
sites via the  “ common mucosal immune 
system ” . 2,3 Gut-associated lymyphoid 
tissue — the subset of MALT that exists in 
the gastrointestinal tract — is a major site 
for induction of T regulatory cells neces-
sary for microbial tolerance. 4 With recog-
nition of the common mucosal immune 
system and its unique properties, the 
development of mucosal vaccines and 
therapies has become an area of intense 
research interest. 2,5,6 
 In this commentary, we briefl y review 
epidemiological evidence that the clini-
cal outcome of the respiratory infection 
caused by  Mycobacterium tuberculosis 
may be modulated by mucosal infections 
that are endemic in the same populations. 
As examples, we focus on  Helicobacter 
pylori and gastro-intestinal helminthiasis, 
two major gut-associated  “ pathobiontic ” 
infections that frequently co-exist in TB-
infected hosts ( Figure 1 ). We propose 
that colonization with these pathogens 
exerts competitive eff ects on regulation of 
the immune response to  M. tuberculosis : 
 H. pylori promoting a Th 1-type response 
consistent with control of TB, and helmin-
thiasis promoting a Th 2-type response that 
may disregulate responses to tuberculosis 
(TB). In each case, the newly recognized 
Th17 lineage 7 – 10 may also have a role. 
Th ese lines of investigation are just begin-
ning, and further mechanistic as well as 
immuno-epidemiological research is 
needed. Understanding how common, nat-
urally occurring mucosal infections infl u-
ence immunity to TB may lead to further 
insights into the therapeutic properties of 
the common mucosal immune system. 
 INTRODUCTION 
 Th e mucosa of the gastrointestinal and 
respiratory tracts comprise the largest 
surfaces in contact with the external 
milieu. Th is system is designed to pro-
vide a physico-chemical barrier against 
dissemination of pathogenic mircroor-
ganisms while sampling a vast array of 
foreign antigens, presenting them to the 
immune system, and adapting them to the 
presence of foreign microbial communi-
ties. 1 In addition to pattern recognition 
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 IMMUNO-EPIDEMIOLOGY OF TB 
 Th e intracellular pathogen  M. tuberculosis 
has co-existed in human populations 
for at least 50,000 years. 11 Spread from 
person to person via aerosol droplets, 
 M. tuberculosis infects one-third of the 
world ’ s population, or over 2 billion 
people. Despite dramatic declines in inci-
dence and prevalence of TB infection in 
industrialized countries, there are over 
8 million new cases of  M. tuberculosis , 1.5 
million deaths, and 40 million new infec-
tions each year. 12 Although TB typically 
occurs in poor socio-economic condi-
tions, even under these circumstances, 
a competent human immune system is 
equipped to control the infection. Of 
those exposed to TB, only 30 % 13,14 are 
thought to develop the state of latent 
infection, during which the host remains 
clinically well, but bacilli survive within 
T-cell activated granulomas in a dormant 
or slowly replicating state. 15 Of those 
harboring a latent infection, on average, 
only 5 – 10 % will progress to active clini-
cal disease, the majority within 2 – 3 years 
of exposure. Approximately 50 % of those 
with active disease will survive without 
treatment, although each could infect 
an additional 10 – 20 contacts during the 
period of active disease. 12,16 
 Protective immunity to TB is predomi-
nately cell-mediated and incompletely 
understood. Although the precise mech-
anisms are controversial, TLR-medi-
ated innate immunity and microbicides 
present in the airways, and are likely to 
play a role in resistance during the ini-
tial phases of acute infection. 17 Th e only 
vaccine currently in use, the live attenu-
ated  M. bovis -derived Bacille – Calmette –
 Guerin (BCG) vaccine, stimulates a wide 
spectrum of cellular immune responses, 
but has highly variable effi  cacy, and does 
not protect against adult pulmonary 
disease. 18,19 Based on animal models of 
BCG vaccination, T-cell recall responses 
are delayed approximately 2 weeks post-
challenge, representing a significant 
delay in T-cell priming. 20 For this reason, 
mucosal Th 17 vaccines based on early 
recruitment of neutrophils with produc-
tion of interleukin (IL)-17 and mediators 
such as IL-23 in the alveolar passages are a 
promising area of investigation. 9 Mucos-
ally administered TB vaccines may off er 
properties superior to the intramuscular 
route. 21 
 With the establishment of latent 
 M. tuberculosis infection, a network of 
pro-infl ammatory and regulatory circuits 
is invoked to sequester bacilli-infected 
macrophages within granulomae. Both 
tumor necrosis factor-  and interferon 
(IFN)-  derived from activated T cells 
appear to be essential for maintaining the 
integrity of granulomae and preventing 
reactivation. 22 Central memory T-cells 
expressing IL-2 also appear to be impor-
tant for clearance of infection and resolu-
tion of fi brosis. 23 – 25 To circumvent these 
defenses,  M. tuberculosis inhibits phagoly-
somic fusion and acidification within 
macrophages. 15,26 In household-contact 
biomarker studies, early progression has 
been associated with alterations in the 
production of regulatory Th -2 cytokines, 
such as IL-4 and IL-10. 27,28 Th us, the bal-
ance of eff ector and suppressive immune 
responses appears to be important in 
the host ’ s prolonged management of TB 
infection. 29 In longitudinal studies, many 
acquired immuno-suppressive condi-
tions are known to disrupt this balance 
 Figure 1   Hypothetical framework for interaction of protective immune responses to  Mycobacterium tuberculosis ( Mtb ) infection in the setting of 
( a )  H. pylori , ( b ) intestinal helminth, and ( c ) triple infection: ( a )  Mtb / H. pylori coinfection may enhance pro-inflammatory signals (e.g., interferon (IFN)-  ) 
involved in control of TB infection, 68,85 while ( b )  Mtb / helminth co-infection may suppress pro-inflammatory responses to  Mtb infection via the Th2 
pathway. 53,54 The presence of all three infections ( c ) would be expected to heighten pro-inflammatory and anti-inflammatory signals. Also, as shown in 
( d ),  H. pylori and helminth co-infection may suppress proinflammatory responses to  H. pylori infection. 81,82 IL, interleukin; TNF, tumor necrosis factor. 
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and increase the risk of active disease, 
including HIV infection, 30,31 malnutri-
tion, 32 Vitamin D deficiency, 33 diabe-
tes, 34 and anti-tumor necrosis factor-  
therapy. 35 With insights from systems 
biology models, a dynamic spectrum of 
TB infection, continuously mediated by 
micro-environmental factors, has been 
postulated. 17,36 Understanding the role 
of concurrent mucosal infections like 
 H. pylori and gastro-intestinal helminthi-
asis may lead to better delineation of this 
spectrum. 
 INTESTINAL HELMINTHS AND 
 M. TUBERCULOSIS 
 Over a quarter of the world ’ s population is 
infected with the soil-transmitted intesti-
nal helminths, including the roundworm 
 Ascaris lumbricoides , the hookworms 
 Necatoramericanus and  Ancylostomaduo-
denale , the whipworm  Trichuristrichiura , 
and  Enterobiusvermicularis , and  Strongy-
loides spp. 37,38 Despite their species diver-
sity, gastrointestinal helminths (and also 
many non-mucosalworms) elicit a stere-
otypic human immune response. Clas-
sically, this is characterized by secretion 
of IgE and IgG4 isotype with concurrent 
eosinophilia, 39 and polarization of CD4  + 
T cells towards a Th 2 phenotype, 40 – 42 on 
which expulsion depends. 43 Th is  “ modi-
fi ed ” Th 2 phenotype is associated with 
production of the cytokines IL-4, IL-9, 
IL-10, IL-13, 44 as well as induction 
of Foxp3  +  Treg cells and regulatory 
cytokines TGF-  and IL-10. 45 In endemic 
regions, worm burdens tend to peak by 
adolescence, suggesting the develop-
ment of partial resistance with age. 40 
Conversely, the virtual disappearance of 
helminths from the human microbiome 
of high-income countries has been linked 
with the rise in atopic and auto-immune 
conditions, 46 possibly due to eff ects on 
Treg induction. Based on these fi ndings, 
helminth-based therapies for conditions 
such as multiple sclerosis and infl amma-
tory bowel disease are an active area of 
investigation. 47,48 
 Although there are few studies, epi-
demiological evidence suggests that 
helminth infections may diminish 
immune responses to TB antigens. 
In humans, chronic intestinal helmi-
nathiasis is associated with immune 
hypo- responsiveness, 49,50 including a 
 “ bystander effect ” , to oral cholera 51,52 
and BCG vaccines. 53 In a randomized 
control trial, Elias  et al. 54 reported that 
albendazole deworming was associated 
with signifi cant improvements in purifi ed 
protein derivative-induced IFN-  produc-
tion following BCG vaccination of Ethio-
pian adults. In a second trial, this team 
also reported that co-infected adults not 
receiving anti-helminthic treatment had 
increased production of PPD-induced 
TGF-  3 months following BCG vaccina-
tion. 53 In a Brazilian cohort, TB patients 
with intestinal parasites had lower IFN-  
and higher IL-10 levels compared with 
TB patients without intestinal parasites. 55 
In  in vitro T-cell functional studies in 
blood from Indonesian school children, 
researchers found that geohelminth-
associated regulatory T-cell responses 
suppressed IFN-  responses to BCG and 
 Plasmodium falciparum , an eff ect that was 
reversed with removal of CD4  +  CD25 hi T 
cells. 56 Th ese studies off er evidence that 
both infl ammatory and regulatory sig-
nals involved in control of TB infection 
can be modifi ed by concurrent intestinal 
helminth infection. Some fi larial worms 
and tissue-invasive cestodes, beyond the 
scope of this commentary, are also thought 
to aff ect responsiveness to mycobacterial 
antigens, although the mechanisms may 
diff er. 49 Although environmental myco-
bacteria are widely considered to block 
immune responses to TB antigens, 57 their 
distribution does not account for the wide 
variability in responses to BCG. Th e role 
of concurrent helminth infections needs 
to be more systematically explored in the 
context of TB vaccine and immunogenic-
ity trials. 
 H. PYLORI AND  M. TUBERCULOSIS 
 H.pylori , a bacterium that colonizes the 
gastric mucosa and epithelial lining of the 
human stomach, remains one of the most 
common chronic mucosal infections in 
the world, 58 infecting approximately 80 % 
of those in TB-endemic regions. Typi-
cally acquired in early life via oral – oral 
or fecal – oral pathways, 59 chronic infec-
tion is now known to be the preeminent 
cause of gastric cancer and peptic ulcer 
disease. 60 – 62 All infected hosts develop a 
superfi cial gastritis that typically persists 
asymptomatically for many decades. In 
addition to specifi c IgA, IgM, and IgG 
responses, this gastritis is associated with 
induction of IL-8 by epithelial cells, 63 as 
well as a locally vigorous, cell-mediated 
immune response, characterized by 
increased mucosal concentrations of the 
infl ammatory cytokines IFN-  , tumor 
necrosis factor-  , IL-1  , and IL-6. 64 Th e 
cytokine IL-12 is present in large num-
bers of mononuclear cells and appears 
to be involved in differentiating naive 
T-cells into a Th 1 phenotype. 65 Although 
the predominate profile during infec-
tion is infl ammatory, the IL4 antagonist, 
IL-4  2, T-regulatory-activated IL-10, as 
well as B-cell responses, may be permis-
sive for chronic  H. pylori colonization via 
counter-regulatory mechanisms. 66 Th e 
role of IL-17 in infl ammation and recruit-
ment of neutrophils at the site of infection 
is an area of intense investigation. 67,68 
 As helminth infections vary with 
respect to their immunological eff ects, 
so too,  H. pylori strains elicit diff erent 
immune responses. 69 Of particular note, 
some  H. pylori strains contain a patho-
genicity island, 70 a 30-gene cassette 
encoding a Type IV secretion system 
that translocates virulence factors to the 
host cytosol. 71 Th is pathogenicity island 
induces increased inflammation with 
higher risk of ulcer disease 72 and gastric 
cancers. 73,74 Host polymorphisms are also 
thought to exacerbate this interaction. 75 
Other differences in  H. pylori strain, 
such as expression of the active form of 
the immunogenic vacuolating antigen 76 
or preservation of the outer membrane 
protein BabA (which mediates adhesion 
to human Le b blood group antigens), may 
also infl uence immunological reactions 
by aff ecting attachment and neutrophil 
recruitment. 64 
 Dramatic declines in the incidence of 
 H. pylori infection occurring in industrial-
ized regions during the twentieth century 
have corresponded with increases in the 
prevalence of allergy-like symptoms 77 as 
well as upper gastrointestinal diseases. 78 
Th ese trends have prompted some inves-
tigators to speculate that in regions of 
high infant mortality, immune-regulated 
 H. pylori infection confers survival advan-
tages against deadlier infections of early 
childhood. 79 For example, in Northern 
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Californian Hispanic households, 
 H. pylori infection was associated with 
protection from household gastroenteri-
tis. 80 Th at concurrent helminth infection 
has been observed to alter the infl am-
matory response to  H. pylori in rodent 81 
and human 82 studies could support the 
notion that the two infections exert 
competitive regulatory eff ects on cell-
mediated immunity when present in the 
same host. 
 Because social conditions contribut-
ing to the prevalence of  M. tuberculosis 
and  H. pylori are similar, cross-sectional 
studies of disease association tend to yield 
confl icting results. 83,84 Few studies have 
correlated immune responses to  H. pylori 
and TB infection in co-infected hosts. In 
a preliminary fi nding, we have reported 
that Northern Californians seropositive 
for  H. pylori and testing positive for latent 
TB have enhanced IFN-  production and 
a dominant Th 1-type cytokine profi le in 
response to specifi c TB antigens. 85 We 
also reported that, compared with latently 
infected household contacts who did not 
progress to active TB disease during 
2 years of follow-up, Gambian TB patients 
were one-third as likely to be  H. pylori 
seropositive. However, in Gambian and 
Pakistani household contacts exposed 
to an infectious case of TB, baseline 
 H. pylori infection was not associated with 
secondary case activation aft er 2 years. 
In cynomolgus macaques, those with nat-
ural  H. pylori infection were one-third as 
likely to progress to TB 6 – 8 months aft er 
 M. tuberculosis challenge. 85 Although 
these lines of investigation provide pre-
liminary evidence of enhanced immunity 
to TB with  H. pylori infection, challenges 
in study design remain to be overcome. 
Th ese include the relatively poor predic-
tive value of immunodiagnostics in the 
setting of primary progressive TB, 86 the 
need to identify more prevalent inter-
mediate markers of progression, and 
the suboptimal performance of  H. pylori 
serology in the developing world. 85 
 If  H. pylori influences the immune 
response to TB infection, there are sev-
eral possible mechanisms. For example, 
H. pylori could promote a  “ Th2 – Th1 
switch ” in early life, such that Th 1-type 
responses to an unrelated MALT infec-
tion are permanently heightened. Such 
a  “ hygiene hypothesis ” has been pro-
posed for hepatitus A virus. 87 Studies 
comparing BCG immunogenicity in 
infants and adolescents from develop-
ing and industrialized countries also 
support this type of phenomenon. 88 In 
a second model, active, asymptomatic, 
H. pylori gastritis would provide a con-
tinuous source of infl ammatory stimu-
lation. Such a  “ bystander ” model was 
recently described for mice infected 
with mucosal herpes viridae and pro-
tected from subsequent challenge by 
 Y. pestis and  L. monocytogenes . Th is model 
may apply uniquely to chronic mucosal 
infections. 89 Th ough more speculative, 
 H. pylori -induced IL-17 might have a role 
in early T-cell recruitment to the lung 
compartment, thereby enhancing initial 
resistance to latent TB infection. Another 
possibility is that dysregulation of the 
 H. pylori -associated gastric T-regulatory 
system compromises systemic Th1 
responses involved in control of a TB 
infection. In separate laboratory studies, 
the IL-4 inhibitor, IL4  2 splice variant, 
has been implicated both in upregula-
tion of the Th 1 dominant  H. pylori Cag 
A response 90 and downregulation of the 
Th 2-mediated response associated with 
progression of latent TB infection. 91 
 TOWARD A MICROBIOMIC PERSPECTIVE 
 Th e human immune system has evolved 
in the face of a panoply of commen-
sal and mutual infections. 92 Classic 
mucosal defenses, including organo-
genesis of lymphoid follicles, induction 
of secretory IgA, and recruitment of the 
cell-mediated armentarium appear to be 
seeded and orchestrated by the establish-
ment of microbrial communities in early 
life. 93,94 Growing evidence implicates the 
human microbiome as a major regulator 
of immunopathologies associated with 
diverse conditions such as infl ammatory 
bowel disease, 95 obesity, 96 allergies, 97 and 
even psychopathology. 98 Understanding 
the interactions of naturally occurring 
mucosal infections such as  H. pylori , intes-
tinal helminths, and  M. tuberculosis —
 three distinct parasitic infections present 
in the same ecosystem for millennia, exert-
ing contrasting immunoregulatory eff ects, 
to which the normal human immune is 
substantially adapted — off ers a potentially 
informative  “ microbiomic ” perspective for 
vaccine and immunodiagnostic research. 
The evidence presented here remains 
preliminary and belies the need for more 
original work. Th e research infrastruc-
ture now assembled for TB vaccine trials 
provides a well-organized platform to roll 
out interdisciplinary prospective studies 
of major public health importance. 
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